BreezeMeds

Provider Profile Name: BreezeMeds
Legal Entity: Breezemeds, Inc.
Headquarters: Marietta, Georgia
Website: breezemeds.com
Provider Type: Telehealth — Virtual Only, Direct-to-Consumer

Operating Details

• Fully virtual — no in-person visits required
• Three-entity model: telehealth platform, independent licensed providers, and 503A partner pharmacies
• FSA and HSA payments accepted
• No subscription required, according to company promotional materials
• Nationwide availability not confirmed — state availability should be verified directly

Approach BreezeMeds is a direct-to-consumer telehealth platform that connects individuals with licensed healthcare providers and partner compounding pharmacies for access to prescription GLP-1 weight loss medications. The company describes the program as medically supervised weight loss personalized to each patient through a fully online process — completing a health assessment online, having a licensed provider review information and determine whether a prescription is appropriate, and medication shipping to the door.

About the Company

BreezeMeds is operated by Breezemeds, Inc. and offers compounded semaglutide injections, oral semaglutide, and oral tirzepatide according to its website. The company’s press releases are filed from Marietta, Georgia, indicating that as its base of operations.

One area where BreezeMeds meaningfully differentiates itself from most compounded GLP-1 telehealth platforms is its oral medication options — offering both oral semaglutide and oral tirzepatide as dissolvable daily tablets alongside traditional weekly injections. This makes it one of a relatively small number of platforms catering explicitly to patients who prefer not to self-inject.

Medical decisions and prescribing are handled by independently licensed clinicians, not by the platform itself. This distinction can be confirmed in the company’s terms of service. Like most platforms in this space, BreezeMeds operates a three-entity model — separating the technology platform from the medical practice and the compounding pharmacy — which is standard industry structure but means patients should understand which entity to contact for clinical concerns versus billing concerns.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

No founding date, named medical director, or leadership team is publicly identified on the company’s website or in press materials reviewed for this article. Prospective patients who value knowing who oversees their clinical care may want to ask this directly during the intake process.

GLP-1 Offerings and Weight Loss Services

BreezeMeds offers three GLP-1 medication formats — a broader selection than most compounded-only platforms, which typically offer injectable semaglutide and tirzepatide only:

GLP-1 and Related Medications:

• Compounded Semaglutide Injection — one injection per week
• Compounded Oral Semaglutide — one dissolvable tablet per day
• Compounded Oral Tirzepatide — one dissolvable tablet per day
• Sermorelin Injections — listed separately from the GLP-1 offerings as a complementary longevity and metabolism option

The oral formats are a notable differentiator. Compounded oral tirzepatide in particular is uncommon — most platforms exclusively offer injectable tirzepatide. However, patients should be aware that oral compounded GLP-1 formulations use delivery methods that differ significantly from FDA-approved oral semaglutide (Wegovy tablets), which uses a specialized absorption technology (SNAC) not present in most compounded oral versions. The clinical effectiveness of compounded oral formulations has not been studied in the same way as injectable GLP-1s or FDA-approved oral Wegovy.

All compounded formulations are not FDA-approved finished products and have not been evaluated by the FDA for safety, effectiveness, or quality as finished formulations. The compounded versions contain the same active ingredient as branded GLP-1 medications but differences in formulation, concentration, and preparation methods may exist.

Pricing by Type — and What Reviewers Say

BreezeMeds operates as a telehealth platform offering compounded GLP-1 weight loss medications with published pricing starting at $199 per month for injectable semaglutide, $299 for oral semaglutide, and $399 for oral tirzepatide, according to the company’s website as of February 2026.

Published Monthly Pricing:

• Compounded Semaglutide Injection: from $199/month
• Compounded Oral Semaglutide: from $299/month
• Compounded Oral Tirzepatide: from $399/month
• Sermorelin Injections: from $100

The company advertises FSA and HSA eligibility and states that no subscription is required, according to promotional materials on the website. Pricing and program terms are subject to change and may vary based on clinical evaluation, dosing, and individual health factors.

Compared to the broader market, BreezeMeds’ semaglutide injection pricing ($199/month) is competitive — sitting in the lower range of compounded semaglutide platforms nationally. The oral tirzepatide option at $399/month is higher than standard injectable tirzepatide programs but reflects the relative rarity of this format. One item worth confirming before enrolling: what “no subscription required” means in practice — whether single purchases are available, whether ongoing treatment involves recurring payments, and what the specific payment and renewal terms are.

What reviewers say about pricing over time: No substantial volume of independent patient pricing reviews was found for BreezeMeds across major platforms. The available affiliate-driven review articles cite company-stated pricing without independent patient confirmation of long-term cost experiences. Prospective patients should verify directly whether pricing remains flat as doses titrate upward, or whether costs increase at higher maintenance doses — a critical question that third-party patient reviews would normally answer but cannot here due to limited public feedback.

Reviews from Trustpilot and Google

This is the most significant gap in the BreezeMeds profile. A search of Trustpilot found only one review associated with a BreezeMeds-linked domain, providing no meaningful data. No verified Google Business profile reviews were identified. BreezeMeds does not appear in major independent GLP-1 comparison rankings on sites such as U.S. News, Healthline, or major review aggregators that evaluate well-established platforms.

The reviews that do exist online are largely found on affiliate marketing pages — articles written to earn a commission from BreezeMeds referrals. One such article claims a “5/5 rating from over 50,000+ reviews,” a figure that is not verifiable through any public third-party platform and should be treated with skepticism.

This is a meaningful transparency gap. Unlike Belle Health (425 Trustpilot reviews), Measured (382 reviews at 4.9 stars), or Amazon One Medical (280+ reviews), BreezeMeds has essentially no independent patient feedback trail at the time of writing. This does not necessarily mean the service is poor — it may simply be newer or smaller — but it does mean prospective patients cannot assess real-world experiences with shipping, medication quality, customer service, or long-term pricing through verified channels.

What affiliate-style reviews report (unverified):

• Patients reportedly losing 10–35 lbs over 3–6 months
• Mild initial nausea noted but resolving quickly
• Customer support described as helpful and responsive
• Delivery noted as slightly slower than desired by some

These reports should be treated as marketing-adjacent rather than independent verification.

Compounding Pharmacies Used

BreezeMeds uses a 503A compounding pharmacy framework to facilitate access to prescription weight management medications. The specific names of its partner pharmacies are not publicly disclosed in any materials reviewed for this article.

This matters for two reasons. First, pharmacy quality varies significantly between 503A facilities, and without knowing which pharmacy fills prescriptions, patients cannot independently verify licensing, accreditation, or batch testing practices. Second, the current regulatory environment makes pharmacy identity more important than ever:

The semaglutide drug shortage was officially resolved in February 2025, and tirzepatide was removed from the shortage list in late 2024. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are generally prohibited from producing drugs that are essentially copies of commercially available FDA-approved products. During the shortage that rule was relaxed. Now it is not. There are limited exceptions under Section 503A that allow compounding when a prescriber determines a patient’s specific medical needs cannot be met by an FDA-approved drug.

Patients considering BreezeMeds should ask directly:

• Which licensed compounding pharmacy fills their specific prescription
• Whether the pharmacy is 503A or 503B designated
• Whether a Certificate of Analysis (CoA) is available for each batch
• How the prescribing provider documents the patient-specific medical need that justifies compounding under current post-shortage regulations

Note: All pricing reflects BreezeMeds’ published rates as of February 2026 per GlobeNewswire and related press materials, and is subject to change. No verified third-party Trustpilot or Google reviews were found for BreezeMeds at the time of writing — prospective patients are strongly encouraged to seek independent reviews and confirm pharmacy partner identity before enrolling. Compounding pharmacy partners are not publicly named. “No subscription required” terms should be confirmed directly with BreezeMeds before purchase. Always consult a licensed medical provider before beginning any GLP-1 program.